BRIEF-Aeglea says first presentation to include initial data from phase 1, open-label study of AEB1102
January 17, 2017 at 16:11 PM EST
* Aeglea Bio Therapeutics - First presentation to include initial data from Phase 1, open-label study of AEB1102 in two adult patients with Arginase I deficiency
